Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their resubmitted supplemental biologics license ...

Jasper Therapeutics faces financial challenges but strong buy ratings. Read why JSPR stock is poised for growth amid risks ...

The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.

Analyst Ami Fadia of Needham maintained a Buy rating on Blueprint Medicines (BPMC – Research Report), retaining the price target of ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...

ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, <a target= ...

Antihistamines for systemic use constituted the majority of additional medications for urticaria used in all treatment groups (100% in the levocetirizine and 78.8% in the placebo group).

In November 2021, however, she came up against a case nearly impossible to solve. It all started when Elisha woke up with an ...

Frieden was director of the Centers for Disease Control and Prevention from 2009-2017. Donald Trump and Robert F. Kennedy Jr.’s campaign to “Make America Healthy Again” gets some things ...

Medically reviewed by Jurairat J. Molina, MD Acute urticaria (hives) is a common skin condition that affects up to 20% of people at some point in their lives. It can transition into chronic urticaria ...